Phase 2 N=7 AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants That Experienced a Dose Limiting Toxicity — 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=114 A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
Hypertension
Primary: Change From Baseline in Ascending Aorta Distensibility at 52 Week — 0.269; 0.330 10^(-3) x mmHg^(-1) — p=0.7324
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
Phase 3 N=280 Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring
Sleep Apnea Syndromes
Primary: Nightly CPAP Adherence — 3.7; 3.7; 3.7; 3.2 hours per night — p=0.50
N/A N=132 Prolonged Exposure (PE) for Post Traumatic Stress Disorder (PTSD): Telemedicine Versus In Person
PTSD
Primary: Treatment Completion — 7.6; 8.6; 3.1; 2.9 sessions
Phase 2 N=32 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Response Rate(CR/CRi) Rate — 6; 9 participants
Phase 1 N=20 The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)
HIV Infection
Primary: Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hrs (AUC 0-24hr) of Raltegravir Following Once Daily Administration of Raltegravir — 53.7; 14.8; 46.3…
N/A N=82 Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
Catheter Site Discomfort · Complications · Anesthesia
Primary: Catheter-related Bladder Discomfort — 35; 24 participants
N/A N=159 Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia
Critical Illness · Hyperglycemia · Dietary Modification
Primary: Measure of Biochemical Parameters and Evaluation of Infectious Complications 1 — 138.6; 146.1; 143.9; 146.1 mg/dL
Phase 4 N=51 Methylphenidate Treatment of Attention Deficits in Epilepsy
Epilepsy · Cognitive Deficits · Attention Deficits
Primary: Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables) — -3.3; -3.58; -3.66; 0.19 Units — p=0.037
N/A N=322 Evaluation of an Investigational Multifocal Lens
Presbyopia
Primary: Overall Quality of Vision Using the Contact Lens User Experience (CLUE) TM Questionnaire — 51.15; 54.28; 53.55; 51.84 units on a scale
N/A N=466 Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication
Bradycardia
Primary: Freedom From RA and RV Lead-related Complications — 97.19; 99.14 percentage of participants
Phase 1 N=6 Oral Bioavailability and Mass Balance Trial With Pimasertib
Locally Advanced or Metastatic Solid Tumors
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of [14C]-Pimasertib Following Intravenous (IV) Administration on…
N/A N=173 Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies
Healthy
Primary: Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ — -0.1946; -0.6772…
Phase 2 N=209 A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate in Breast After 12 Weeks of Therapy — 24.9; 23.4; 6.9; 9.1 Percentage of Participants